Assembly Bio aspires to deliver finite and curative therapies for chronic hepatitis B virus (HBV) infection, one of the world’s most prevalent and devastating infectious diseases.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights
- Assembly Biosciences Announces Program Reprioritization and Organizational Update
- Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
Jul 26, 2022 at 4:30 PM EDT
Jun 22 - Jun 26, 2022
Mar 31, 2022 at 11:00 AM EDT